Insider · CIK 0001826732
Jorge DiMartino
Files at KRON (Kronos Bio, Inc.). First filing Dec 14, 2022, latest Jan 5, 2024.
In brief
Jorge DiMartino files SEC Form 4 as officer at KRON (Kronos Bio, Inc.). Since Dec 14, 2022, Jorge DiMartino has reported 0 open-market buys worth $0 and 3 open-market sells worth $71k, the latest filed on Jan 5, 2024.
A track record needs three past buys with six months of prices behind them; Jorge DiMartino has 0, so none is measured yet.
The newest scored trade: sold $14k of KRON on Jan 4, 2024, filed Jan 5, 2024, scored 30 (weak).
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 30Weak | Kronos Bio, Inc. | $14k 12,009 shares | -4% | - | |
| 23Weak | Kronos Bio, Inc. | $23k 17,367 shares | -5% | - | |
| 29Weak | Kronos Bio, Inc. | $34k 18,657 shares | -8% | - |
Transactions
Every row this insider has filed, 3 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jan 4, 2024 | KRON Kronos Bio, Inc. | SOpen-market sale Common Stock | -12,009 | $1.18 | $14k | 315,246 | Jan 5, 2024 |
| Dec 12, 2023 | KRON Kronos Bio, Inc. | SOpen-market sale Common Stock | -17,367 | $1.31 | $23k | 327,255 | Dec 13, 2023 |
| Dec 12, 2022 | KRON Kronos Bio, Inc. | SOpen-market sale Common Stock | -18,657 | $1.81 | $34k | 219,478 | Dec 14, 2022 |
Questions about Jorge DiMartino
Answered from the filings on this page, as of the latest one.
Is Jorge DiMartino buying or selling?
Not in the last 12 months. Jorge DiMartino's latest open-market trade on SEC Form 4 was sold $14k of KRON on Jan 4, 2024.
How did Jorge DiMartino's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Jorge DiMartino has 0.
Where does Jorge DiMartino file Form 4?
Jorge DiMartino has filed Form 4 at KRON (Kronos Bio, Inc.) as Chief Medical Officer & VP. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.